Part 1/8:
The Journey of CAR-T Therapy: A Market Reality Check
The CAR-T hype train, heralded as a revolutionary advance in cancer treatment, has begun its trek into the biopharmaceutical market as of 2018. In 2017, anticipation was high among investors and stakeholders regarding CAR-T technologies, which promised to supercharge the body’s immune system to fight cancer. However, as evident through the financial results of prominent players in the field, the journey from concept to commercial success is fraught with challenges.